Creating a workable generic drug user fee programme in the US
This article was originally published in SRA
Generic medicines are a critical component of the US healthcare system. Access to low-cost generic prescription drugs allows millions of Americans to comply with their doctors' medication orders while saving billions of dollars in costs. But the growth of the generics industry, coupled with a chronic lack of resources for the Food and Drug Administration's Office of Generic Drugs, has created a situation that neither the industry nor the agency considers acceptable.
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.